BeneVir Biopharm, Inc.
- Headquarters
- Gaithersburg, MD
- Founded
- 2011
- Latest Form D
- $2M, Nov 2017
- Total capital
- $7.4M
- Federal grants
- $423K
- 2 awards · 2012
- Private capital raised
- $7M
- 3 Form D · last Nov 2017
- 107 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 3 pending · first 2018
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$2M
- Private capital raisedForm D · SEC · 2nd filing$3M
- Private capital raisedForm D · SEC · 1st filing$2M
- Federal grantHealth and Human S · N43 · R&d- Medical: Biomedical (basic Research)$200K
- Federal grantHealth and Human S · Phase I · Avirulent CD8+ T-cell Evading Oncolytic HSV-1 for the Treatment of Bladder Cancer$223K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
26months
from BeneVir Biopharm, Inc.’s first federal award to its first private round.
- First federal award · Sep 2012
- Health and Human S · $223K
- First Form D · Nov 2014
- $2M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Founders and team
Researcher links verified by same-company patents and grants- Matthew Charles MulveyResearcherExecutive Officer, DirectorLinked by 1 patent · $200K in grants as PI
- Cherine Charles PlumakerDirectorNamed in SEC Form D filings
- David Charles KirnDirectorNamed in SEC Form D filings
- David Charles PresentDirectorNamed in SEC Form D filings
- Katherine Ann SackstederExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 7- PendingOncolytic Herpes Simplex Virus And Therapeutic Uses ThereofUSPTOApplication 17502700
- GrantedOncolytic Herpes Simplex Virus and Therapeutic Uses ThereofUSPTOUS 11,147,846
- GrantedOncolytic Herpes Simplex Virus and Therapeutic Uses ThereofUSPTOUS 10,456,432
Show all 7 patent records
- Oncolytic Herpes Simplex Virus And Therapeutic Uses ThereofFeb 3, 2022 · Application 17502700Pending
- Oncolytic Herpes Simplex Virus and Therapeutic Uses ThereofOct 19, 2021 · US 11,147,846Granted
- Oncolytic Herpes Simplex Virus and Therapeutic Uses ThereofOct 29, 2019 · US 10,456,432Granted
- Exogenous Tap Inhibitor Armed Oncolytic Viruses And Therapeutic Uses ThereofMar 19, 2019 · US 10,232,003Granted
- Oncolytic Herpes Simplex Virus And Therapeutic Uses ThereofOct 23, 2018 · US 10,105,404Granted
- Exogenous Tap Inhibitor Armed Oncolytic Viruses And Therapeutic Uses ThereofApplication PCTUS2015023268Pending
- Oncolytic Herpes Simplex Virus And Therapeutic Uses ThereofApplication PCTUS2012054206Pending
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .